Page 88 - Sohini Das

Cipla settles blood cancer drug litigation with Bristol Myers in US

As it takes away the legal overhang, Cipla can launch the drug once its ANDA is approved

Gennova mRNA vaccine stable above sub-zero temperatures unlike global peers

The messenger RNA vaccine candidate contains a short, synthetic version encoding the spike protein (antigen) of the novel coronavirus Sars-CoV-2

Pune's Gennova gets nod for clinical trials of India's first mRNA vaccine

DCGI granted conditional approval for phase 1 and 2 clinical trials of Gennova's mRNA based Covid-19 vaccine candidate

Review panel asks vaccine makers to submit more data to get authorisation

Experts ask Bharat Biotech for phase 3 data, Serum's UK approval status

Expert panel set to review Pfizer-BioNTech, SII vaccine applications today

ICMR Director General Balram Bhargava said that in the case of temporary licensure or emergency use, the regulator had to be satisfied with the risk-benefit ratio.

Bharat Biotech applies for emergency use authorisation for Covaxin

The company is conducting a 26,000 subjects phase 3 efficacy trial in India to determine the efficacy of its candidate

Serum set for deal with Centre soon; to supply vaccine at Rs 250 a dose

There is still time before SII can start supplying to the low and medium income countries through Gavi

Decoded: What emergency use authorisation of Covid vaccine means for us

After the Indian arm of US pharmaceutical giant Pfizer, the Serum Institute of India has applied to the Drugs Controller General of India (DCGI) seeking emergency use authorisation

Pfizer working on cold storage issues to ensure temperature integrity

The company has developed detailed logistical plans and tools to support effective vaccine transport, storage, and temperature monitoring.

November domestic pharma sales grow just 1% after strong show last month

Oct growth rate was 9.6%; Most big corporates saw volumes drop in November

Vaccine efficacy based on 2 doses: Bharat Biotech after Vij tests positive

Covaxin is an indigenously developed Covid-19 vaccine undergoing a trial on over 26,000 people across 25 sites in India to evaluate the efficacy of the vaccine candidate

DCGI reassures all protocols being followed in Serum's clinical trials

The ethics committee has seven members, including a chairperson who has to be from outside the institution where the trial is being conducted.

Private health care providers gear up for Covid-19 vaccination drive

The industry, on its part, is drafting out the road map for vaccination and where they can chip in.

If all goes well, India may get first Covid-19 vaccine by February

AstraZeneca vaccine is likely to cost Rs 500-600 per dose in the private market

No impact of adverse event on Covid-19 vaccine timelines: Bharat Biotech

The firm said subject was now safe. Though it was reported to the drug regulator within 24 hours, the event turned out to be unrelated to the vaccine.

Tech transfer of Russian Covid vaccine Sputnik V kicks off at Indian sites

In September, DRL and RDIF had tied up to conduct clinical trials and distribute the vaccine in India.

Pfizer ends vaccine trial with 95% success rate, to apply for approval soon

Pfizer and BioNTech said they plan to submit the data to other regulatory agencies around the world.

Moderna's Covid-19 vaccine may come to India through govt route

Players like Indian Immunologicals willing to partner US firm to manufacture here

Moderna's Covid vaccine 94.5% effective, edges over Pfizer on storage

Its vaccine's temperature requirements give it an edge over Pfizer's for distribution in India

Covid-19: Vaccine production is not a problem for India, cold chain is

As India prepares a road map for a Covid-19 vaccination drive next year, the lack of cold chain infrastructure is a key bottleneck